Table 1 Patient characteristics by premalignant condition status.
From: Relationship among three common hematological premalignant conditions
|  | No MBL/MGUS (N = 1151) | MBL only (N = 275) | MGUS only (N = 147) | Both MBL/MGUS (N = 57) | Total (N = 1630) |
|---|---|---|---|---|---|
Sex | |||||
 Female | 679 (59.0%) | 125 (45.5%) | 77 (52.4%) | 29 (50.9%) | 910 (55.8%) |
 Male | 472 (41.0%) | 150 (54.5%) | 70 (47.6%) | 28 (49.1%) | 720 (44.2%) |
Age at MBL screening (years) | |||||
 Median | 63.0 | 70.0 | 68.0 | 72.0 | 65.0 |
 Range | 40.0–89.0 | 43.0–96.0 | 43.0–94.0 | 53.0–94.0 | 40.0–96.0 |
MBL immunophenotype | |||||
 Atypical | – | 12 (4.4%) | – | 5 (8.8%) | 17 (5.1%) |
 CLL-like | – | 240 (87.3%) | – | 42 (73.7%) | 282 (84.9%) |
 Non-CLL-like | – | 23 (8.4%) | – | 10 (17.5%) | 33 (9.9%) |
MBL clonal size | |||||
 HC-MBL | – | 15 (5.5%) | – | 7 (12.3%) | 22 (6.6%) |
 LC-MBL | – | 260 (94.5%) | – | 50 (87.7%) | 310 (93.4%) |
MGUS heavy chain isotype | |||||
 Missing | – | – | 1 | 0 | 1427 |
 Biclonal | – | – | 8 (5.5%) | 6 (10.5%) | 14 (6.9%) |
 IgA | – | – | 21 (14.4%) | 10 (17.5%) | 31 (15.3%) |
 IgG | – | – | 96 (65.8%) | 33 (57.9%) | 129 (63.5%) |
 IgM | – | – | 21 (14.4%) | 8 (14.0%) | 29 (14.3%) |
M-Spike (g/dl) | |||||
 Missing | – | – | 13 | – | – |
 <0.2 | – | – | 103 (75.2%) | 41 (74.5%) | 144 (75.0%) |
 0.2–1.5 | – | – | 29 (21.2%) | 13 (23.6%) | 42 (21.9%) |
 ≥1.5 | – | – | 5 (3.6%) | 1 (1.8%) | 6 (3.1%) |
CH (overall)a | |||||
 Missing | 644 | 2 | 66 | 0 | 712 |
 No | 369 (72.8%) | 198 (72.5%) | 62 (76.5%) | 40 (70.2%) | 669 (72.9%) |
 Yes | 138 (27.2%) | 75 (27.5%) | 19 (23.5%) | 17 (29.8%) | 249 (27.1%) |
 DNMT3A CH | 63 (12.4%) | 37 (13.6%) | 5 (6.2%) | 4 (7.0%) | 109 (11.9%) |
 TET2 CH | 45 (8.9%) | 18 (6.6%) | 10 (12.3%) | 4 (7.0%) | 77 (8.4%) |
 ASXL1 CH | 10 (2.0%) | 4 (1.5%) | 1 (1.2%) | 3 (5.3%) | 18 (2.0%) |
 nonDTA CH | 41 (8.1%) | 28 (10.3%) | 8 (9.9%) | 10 (17.5%) | 87 (9.5%) |
